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Diverse oxidative pathways, such as direct oxidation
of amino acids, glycoxidation, and lipoxidation could
contribute to Alzheimer disease pathogenesis. A global
survey for the amount of structurally characterized
probes for these reactions is lacking and could over-
come the lack of specificity derived from measurement
of 2,4-dinitrophenylhydrazine reactive carbonyls. Con-
sequently we analyzed (i) the presence and concentra-
tions of glutamic and aminoadipic semialdehydes, N-
(carboxymethyl)-lysine, N-(carboxyethyl)-lysine, and
N-(malondialdehyde)-lysine by means of gas chroma-
tography/mass spectrometry, (ii) the biological response
through expression of the receptor for advanced glyca-
tion end products, (iii) the fatty acid composition in
brain samples from Alzheimer disease patients and age-
matched controls, and (iv) the targets of N-(malondial-
dehyde)-lysine formation in brain cortex by proteomic
techniques. Alzheimer disease was associated with sig-
nificant, although heterogeneous, increases in the con-
centrations of all evaluated markers. Alzheimer disease
samples presented increases in expression of the recep-
tor for advanced glycation end products with high mo-
lecular heterogeneity. Samples from Alzheimer disease
patients also showed content of docosahexaenoic acid,
which increased lipid peroxidizability. In accordance,
N-(malondialdehyde)-lysine formation targeted impor-
tant proteins for both glial and neuronal homeostasis
such as neurofilament L, -tubulin, glial fibrillary acidic
protein, ubiquinol-cytochrome c reductase complex pro-
tein I, and the  chain of ATP synthase. These data
support an important role for lipid peroxidation-
derived protein modifications in Alzheimer disease
pathogenesis.
Oxidative stress-induced molecular alterations affect all
sorts of biological molecules, including especially sensitive
amino acid residues in proteins, such as tyrosine, methionine,
arginine, proline, and lysine, among others (1). Brain aging is
associated with changes increasing the risk of Alzheimer dis-
ease (AD).1 A corollary of this fact is that AD shows an accel-
eration of those phenomena underlying aging. Accordingly, an
increased amount of protein bound 2,4-dinitrophenylhydrazine
(DNP)-reactive carbonyls, generated by protein oxidation are a
common finding in brain samples from AD patients (2). All
these works rely on the reaction of DNP with carbonyl groups.
However, this assay has been criticized because of the possibil-
ity of artifacts (4). The direct measure of the concentration of
structurally characterized products could overcome this fact
and it may be used as a complement for assessing the effects of
oxidative stress in vivo. Glutamic semialdehyde (GSA) derives
from the metal-catalyzed oxidation of proline and arginine,
whereas aminoadipic semialdehyde (AASA) results from lysine
oxidation (5). These products are among the main carbonyl
products of metal-catalyzed oxidation of proteins (5), thus spe-
cific probes of oxidation of amino acids in protein. However,
their presence and the factors affecting their concentrations in
human brains are unknown to date.
The chemical pathways linking increased free radical efflux
and protein structural modification also involve third-party
molecules, which may give rise to increased DNP-reactive car-
bonyls in proteins (6). Particularly, carbohydrates, when react-
ing with free radicals generate highly reactive dicarbonyl com-
pounds, such as glyoxal and methylglyoxal (7). In the cellular
context, these may also be derived from glycolysis, triose phos-
phate metabolism, acetone metabolism (7), lipid peroxidation
(8), and hypochlorite-mediated reactions (9). These compounds
generate stable adducts reacting with lysine, arginine, and
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(carboxymethyl)-lysine (CML) are two of these adducts, first
described as advanced glycation end products (AGE), later
named glycoxidation products and now recognized as mixed
AGEs-advanced lipoxidation products. Despite that CML has
been detected in AD lesions by immunohistochemical analyses
(reviewed in Ref. 10), no chemical evidence have been reported
for this product in AD samples or models. Polyunsaturated
fatty acids (PUFA) are other third-party molecules. PUFA are
molecules very susceptible to the oxidative action of free radi-
cals (11), generating specific reactive aldehydes, such as ma-
londialdehyde or 4-hydroxynonenal, among others (12). These
aldehydes could react with proteins, generating also DNP-
reactive moieties (6). The important PUFA content in brain and
its high oxygen consumption support the possible significance
of lipid peroxidation-derived processes in brain aging and AD
pathogenesis (2). Analogously to the other modifications
pointed out above, evidence for lipid peroxidation-derived pro-
tein damage in AD comprise immunohistochemistry (13). How-
ever, there is no chemical evidence for lipid peroxidative dam-
age of proteins in AD, based on structurally identified
compounds and supported by mass spectrometry.
Concerning the pathogenic role of these products, many re-
cent studies of mechanisms underlying cellular dysfunction in
Alzheimer disease have focused on amyloid -peptide (A).
Persistent chronic inflammation appears to have a significant
role in AD pathogenesis and evidence suggests that the sus-
tained microglial response to A could play a role in this
process (14). In AD brains, the most highly activated microglia
is observed in close association with A plaques (15). In addi-
tion, many inflammatory mediators detected in AD brains are
of microglial origin (14). In vitro, interaction of A with micro-
glia has been shown to cause the induction of a range of in-
flammatory products, including proinflammatory cytokines,
neurotoxic factors, reactive oxygen species, and complement
pathway proteins (15, 16). Multiple A-binding protein or re-
ceptors have been identified on a number of different cell types,
including microglia. They cover cell surface heparan proteogly-
cans and signal transduction receptors (17).
The receptor for advanced glycation end products (RAGE) is
one of these cell surface A-binding proteins (18). RAGE is a
member of the immunoglobulin superfamily of cell surface mol-
ecules whose expression is up-regulated at sites of diverse
pathologies from atherosclerosis to AD (19). The generation of
reactive oxygen species, an early event after ligation of the
receptor, may be fundamental for many RAGE-induced
changes in cellular properties. In the case of neurons, RAGE-
induced cellular activation ultimately results in induction of
programmed cell death (20).
In this work, we attempted to identify and quantify the
amount of oxidation-derived modified amino acids in proteins
from the frontal cerebral cortex of human brains with AD.
Prior, we evaluated the distribution of these protein modifi-
cations by Western blot, the possible influence of sample
preparation in DNP-based outcomes, and studied part of the
biological response to these products by examining RAGE
expression. Finally, given the importance of PUFA in lipid
peroxidation, we also studied the fatty acid profile from these
samples and the identification of major targets of lipoxidative
damage in brain cortex.
MATERIALS AND METHODS
Human Brain Specimens and Reagents—Brain samples were ob-
tained from the Institute of Neuropathology Brain bank following the
guidelines of the local ethics committee. The brains of 8 patients with
AD (four men and four women) and 5 age-matched controls (three
women and two men) were obtained from 2 to 13 h after death, and were
immediately prepared for morphological and biochemical studies. The
agonal state was short with no evidence of acidosis or prolonged hy-
poxia. AD changes were categorized following the nomenclature of
Braak and Braak (21). Stage C of amyloid A4 deposition implicates
involvement of the whole neocortex, whereas stages V and VI of neu-
rofibrillary degeneration indicate moderate and severe involvement of
the neocortex. No additional vascular or degenerative anomalies were
present in these cases. Age-matched controls did not show neuropatho-
logical anomalies, particularly considering the absence of amyloid de-
posits often considered as normal old-age changes. Frozen samples of
the frontal cortex (area 8) were used for biochemical studies. Samples of
control and diseased brains were processed in parallel. Summary of the
main clinical and neuropathological aspects is shown in Table I. Unless
otherwise specified, all reagents were from Aldrich or Sigma, of the
highest purity available.
Distribution of Protein Modifications by Western Blotting and Deri-
vatization of Proteins for Carbonyl Detection—Samples were homoge-
nized in a buffer containing 180 mM KCl, 5 mM MOPS, 2 mM EDTA, 1
mM diethylenetriaminepentaacetic acid, and 1 M butylated hydroxyl
toluene, 10 g/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, pH
7.3 (Potter-Elvehjem device, at 4 °C). After a brief centrifugation (500 g,
5 min) to pellet cellular debris, protein concentrations were measured in
the supernatants using the Lowry assay (Bio-Rad).
Prior to electrophoresis, samples were derivatized with DNP as pre-
viously described (22). Briefly, to 15-l homogenates adjusted to 3.75
g/l of protein, SDS was added to a final concentration of 6%, and after
boiling for 3 min, 20 l of 10 mM DNP in 10% trifluoroacetic acid were
added. After 7 min at room temperature, 20 l of a solution containing
2 M Tris base, 30% glycerol, and 15% -mercaptoethanol were added for
neutralization and sample preparation for loading onto SDS-PAGE
gels. For sample clarification, prior to derivatization, chloroform (2:1,
v/v) was added to an aliquot of the homogenates. Samples were then
vortexed for 1 min and centrifuged at 13,000  g for 10 min. The
proteins in the resulting supernatant were measured using the Bio-Rad
method and equalized.
Immunodetection of Protein-bound 2,4-Dinitrophenylhydrazones, AGEs
and CML—For immunodetection, after SDS-PAGE, proteins were
transferred using a Mini Trans-Blot Transfer Cell (Bio-Rad) to polyvi-
nylidene difluoride membranes (Immobilon-P, Millipore, Bedford, MA).
Immunodetection was performed using as primary antibodies: a rabbit
anti-DNP antiserum (1:4000, Dako, Carpenteria, CA); 6D12, a mono-
clonal anti-CML antibody (1:2000, Transgenic Inc., Kumamoto, Japan);
and a polyclonal anti-AGE antiserum, raised against glyoxilic acid-
treated keyhole limpet hemocyanin (1:2000). Peroxidase-coupled sec-
ondary antibodies were used from the Tropix chemiluminescence kit
(Tropix Inc., Bedford, MA). Luminescence was recorded and quantified
in Lumi-Imager equipment (Boehringer), using the Lumianalyst soft-
ware. Control experiments showed that EDTA presence does not lead to
generation of artifactual oxidation and that omission of the derivatiza-
tion step, primary or secondary antibody addition produced blots with
no detectable signal (data not shown).
Immunodetection of RAGE—A slightly modified protocol was used.
Briefly, samples (0.2g) from diseased and control cases were homoge-
nized in a glass homogenizer in 10 volumes of ice-cold lysis buffer
(Hepes, pH 7.5, 250 mM sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 mM
TABLE I
Summary of the main clinical and neuropathological
findings in the present series
Alzheimer disease, stages C of amyloid-A4 deposition, and stages V
and VI of neurofibrillary degeneration (NFT) according to Braak and
Braak (21) M: male, F: female.
Patient Disease Gender Age
Duration
of the
disease
Post-mortem
Braak stages
Amyloid-A4 NFT
years years h
1 Control F 73 5.3
2 Control M 75 6
3 Control F 79 7
4 Control F 80 3.3
5 Control M 70 6
6 AD M 69 8 6 C V
7 AD F 82 13 10 C V
8 AD F 84 8 2 C V
9 AD F 86 8 10 C V
10 AD M 93 10 7.2 C V
11 AD M 71 6 13 C VI
12 AD M 72 7 6 C VI
13 AD F 72 8 5 C VI
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FIG. 1. AD induces differences in the distribution of protein oxidative modifications and in RAGE expression in homogenates from
brain samples. Protein carbonyl groups, markers of protein oxidative damage, were derivatized with DNPH, and after their separation by SDS-PAGE,
their amount was revealed by immunoblotting (A, left graph). After delipidation, differences between individual bands were more clear (A, right graph).
Western blot analyses measured also AGE (B, upper blot) and CML (B, middle 6D12 blot) protein modifications. Arrows indicate bands noticeably
different in AD samples. Right numbers of the blots indicate apparent molecular weight. The lower panels show the quantitation of these blots by
densitometry. AD also induces differences in RAGE expression as shown by Western blot analyses of individual samples that revealed differences in
distribution and amount of anti-RAGE immunoreactive bands (C shows representative blots from brain cortex of control individuals and AD patients).
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EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 10 g/ml aprotinin, 1
mM phenylmethylsulfonyl fluoride), and centrifuged at 5,000  g for 10
min at 4 °C. Pellet fractions were discarded and protein concentrations
of the supernatants were determined by the bicinchoninic acid method
with bovine serum albumin as a standard.
Samples containing 50 g of protein were loaded onto 10% SDS-
PAGE gels. Proteins were separated by SDS-PAGE and electrophoreti-
cally transferred to nitrocellulose filters. After transfer, the filters were
blocked by incubation with 5% nonfat dry milk in 100 mM Tris-buffered
saline-Tween, containing 140 mM NaCl, 0.1% Tween 20, pH 7.4 (TBS-
T), 1 h at room temperature. Then the filters were incubated overnight
with TBS-T containing 3% bovine serum albumin and anti-RAGE an-
tibody (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at 1:100 dilu-
tion. Next, the filters were washed three times in TBS-T and incubated
with TBS-T containing 5% skimmed milk and horseradish peroxidase-
linked goat immunoglobulins (Dako) diluted 1:1000 for 45 min at room
temperature. Filters were washed several times in TBS-T, and immu-
noreactivity was detected using an enhanced chemiluminescence West-
ern blot detection system (Amersham Biosciences), followed by expo-
sure to ECL HYPER film (Amersham Biosciences). Mouse monoclonal
anti--tubulin at a dilution of 1:5000 was used to ensure equal loading
of samples.
Two-dimensional Electrophoresis—Cortex samples were homoge-
nized in a denaturation buffer (9 M urea, 4% CHAPS, 0.8% 3–11 IPG NL
Buffer (Amersham Biosciences), 1% DTT and protein was quantified.
An aliquot containing 50 g of protein was adjusted to a final volume of
200 l using rehydration buffer (8 M urea, 0,5% CHAPS, 0,5% 3–11 IPG
NL Buffer, 18, 15 mM DTT, and 2% bromphenol blue) and applied
overnight to 3–11 NL 11-cm IPG Strips (Amersham Biosciences). Iso-
electric focusing was performed as follows: 500 V for 3 h, a linear
gradient to 1000 V for 1 h, and finally 6000 V for 3 h in a Bio-Rad
system. Strips were then incubated for 10 min in 37.5 mM Tris-HCl, pH
8.8, containing 6 M urea, 2% (w/v) SDS 20% (v/v) glycerol, and 0.5%
DTT, and then re-equilibrated for 10 min in the same buffer except that
DTT was replaced with 4.5% iodoacetamide. The equilibrated strips
were loaded in a 11% 20-cm long SDS-PAGE gel and run as described
in one-dimensional electrophoresis. Immunoblotting was performed as
described above, using a Semidry transfer system and an anti-MDAL
polyclonal antibody (Academy Biomedical Co., Houston, TX) as primary
antibody (1:2000). For gel staining, a MS-modified silver staining
method (Amersham Biosciences) was used as described by the manu-
facturer. For membrane staining, a silver staining method based on the
Gallyas intensifier was used according to previously described proce-
dures (23).
Image Analysis—The gels (4 for each group) and polyvinylidene
difluoride blots (n  5) were scanned using a GS800 Calibrated Densi-
tometer (Bio-Rad). PDQuest two-dimensional analysis software (Bio-
Rad) was used for matching and analysis of silver-stained gels and
membranes. The average mode of background subtraction was chosen
to compare protein and MDAL immunoreactivity content between cor-
tex samples from AD patients and control individuals. Normalized
intensities of each protein spot from individual gels (or membranes)
were compared between groups by the Student’s t test.
Mass Spectrometry for Protein Identification—After excision from
gel, proteins were reduced with 10 mM DTT and alkylated with 55 mM
iodoacetamide. Enzymatic digestion was performed with trypsin (Pro-
mega, Madison, WI) following conventional procedures as described
(24). After evaporation and redissolution in methanol/water (1:2 v/v),
1% acetic acid, digests were analyzed by matrix-assisted laser desorp-
tion/ionization reflectron time-of-flight (MALDI-reTOF MS).
The MALDI-reTOF MS analysis of the samples was performed using
FIG. 2. Proteins from AD samples show significant increases in
the amounts of GSA and AASA, markers of MCO (upper graph),
and in the concentrations of CML and CEL, arising from gly-
coxidation and lipoxidation (lower graph). Values shown are %
changes of mean  S.E. over values from control samples (GSA,
20,832  350 mol/mol of lysine; AASA, 100  12 mol/mol of lysine;
CML, 497  10 mol/mol of lysine; CEL, 462  14 mol/mol of lysine).
*, p 0.01, and **, p 0.001 respect to control group by Student’s t test.
FIG. 3. Proteins from AD samples show significant increases in
lipid peroxidation-derived damage, as shown by measurements
of MDAL (upper graph), and this is associated with perceptual
changes in peroxidizability index (PI) and DHA content (middle
panel) and a inverse relationship between DHA and docosatet-
raenoic acid content (DTA) (r  0.89; p < 0.0001, lower panel).
Values shown are % changes of mean  S.E. over values from control
samples (MDAL, 260  31 mol/mol of lysine; DHA, 1,143  0.46%;
peroxidizability index, 150.38  2.82) **, p  0.001 respect to control
group by Student’s t test. In the lower panel, triangles (Œ) represent
values from samples of AD patients and circles (●) represent values
from control samples.
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a Voyager DE-PRO MALDI-reTOF mass spectrometer (Applied Biosys-
tems, Foster City, CA). The instrument was run in reflectron mode with
an average resolution of 12,000 full-width half-maximum at m/z 1500.
A 5 mg/ml -cyano-4-hydroxycinnamic solution was used as MALDI
matrix. Spectra were externally calibrated using a standard peptide
mixture consisting of angiotensin II, substance P, bombesin, and adre-
nocorticotropic hormone. When the ions corresponding to known tryp-
sin autolytic peptides (m/z 842.5100 and 2111.1046) were detected, a
second automatic internal calibration of the spectra was performed
using these ions as reference.
Data Base Search—The Protein Prospector software version 4.0.1
(University of California San Francisco, Mass Spectrometry Facility)
was used to identify proteins from the peptide mass fingerprinting
obtained from MALDI-reTOF MS. Swiss-Prot (European Bioinformat-
ics Institute, Heidelberg, Germany) and GenBankTM (National Center
for Biotechnology Information) data bases were used for the search.
Measurement of GSA, AASA, CML, CEL, and MDAL—GSA, AASA,
CML, CEL, and MDAL concentrations in total proteins from cerebral
cortex homogenates were measured by gas chromatography/mass spec-
trometry (GC/MS) as previously described (25). Samples containing
0.75–1 mg of protein were delipidated using chloroform/methanol (2:1,
v/v), and proteins were precipitated by adding 10% trichloroacetic acid
(final concentration) and subsequent centrifugation. Protein samples
were reduced overnight with 500 mM NaBH4 (final concentration) in 0.2
M borate buffer, pH 9.2, containing 1 drop of hexanol as an anti-foam
reagent. Proteins were then reprecipitated by adding 1 ml of 20%
trichloroacetic acid and subsequent centrifugation. The following isoto-
pically labeled internal standards were then added: [2H8]lysine (d8-Lys;
CDN Isotopes); [2H4]CML (d4-CML), [
2H4]CEL (d4-CEL), and
[2H8]MDAL (d8-MDAL), prepared as described (8, 26); and [
2H5]5-
hydroxy-2-aminovaleric acid (for GSA quantization) and [2H4]6-hy-
droxy-2-aminocaproic acid (for AASA quantization) prepared as de-
scribed in Ref. 5. The samples were hydrolyzed at 155 °C for 30 min in
1 ml of 6 N HCl, and then dried in vacuo. The N,O-trifluoroacetyl methyl
ester derivatives of the protein hydrolysate were prepared as previously
described (5). GC/MS analyses were carried out on a Hewlett-Packard
model 6890 gas chromatograph equipped with a 30-m HP-5MS capillary
column (30 m  0.25 mm  0.25 m) coupled to a Hewlett-Packard
model 5973A mass selective detector (Agilent, Barcelona, Spain). The
injection port was maintained at 275 °C; the temperature program was
5 min at 110 °C, then 2 °C/min to 150 °C, then 5 °C/min to 240 °C, then
25 °C/min to 300 °C, and finally hold at 300 °C for 5 min. Quantification
was performed by external standardization using standard curves con-
structed from mixtures of deuterated and non-deuterated standards.
Analytes were detected by selected ion-monitoring GC/MS. The ions
used were: lysine and d8-lysine, m/z 180 and 187, respectively; 5-hy-
droxy-2-aminovaleric acid and d5–5-hydroxy-2-aminovaleric acid (sta-
ble derivatives of GSA), m/z 280 and 285, respectively; 6-hydroxy-2-
aminocaproic acid and d4–6-hydroxy-2-aminocaproic acid (stable
derivatives of AASA), m/z 294 and 298, respectively; CML and d4-CML,
m/z 392 and 396, respectively; CEL and d4-CEL, m/z 379 and 383,
respectively; and MDAL and d8-MDAL, m/z 474 and 482, respectively.
The amounts of products were expressed as the ratio of micromole of
glutamic semialdehyde, aminoadipic semialdehyde, CML, CEL, or
MDAL/mol of lysine.
Fatty Acid Analysis—Fatty acid analysis was performed as previ-
ously described (25). Total lipids from human brain homogenates were
extracted with chloroform/methanol (2:1, v/v) in the presence of 0.01%
butylated hydroxytoluene. The chloroform phase was evaporated under
nitrogen, and the fatty acids were transesterified by incubation in 2.5
ml of 5% methanolic HCl for 90 min at 75 °C. The resulting fatty acid
methyl esters were extracted by adding 2.5 ml of n-pentane and 1 ml of
saturated NaCl solution. The n-pentane phase was separated, evapo-
rated under nitrogen, redissolved in 75 l of carbon disulfide, and 1 l
was used for GC/MS analysis. Separation was performed in a SP2330
capillary column (30 m  0.25 mm  0.20 m) in a Hewlett-Packard
6890 Series II gas chromatograph (Agilent). A Hewlett-Packard 5973A
mass spectrometer was used as detector in the electron-impact mode.
The injection port was maintained at 220 °C, and the detector at 250 °C;
the temperature program was 2 min at 100 °C, then 10 °C/min to
200 °C, then 5 °C/min to 240 °C, and finally hold at 240 °C for 10 min.
Identification of fatty acid methyl esters was made by comparison with
authentic standards and based on mass spectra. Results are expressed
as mol %.
From fatty acid composition, the following indexes were calculated:
saturated fatty acids   % of saturated fatty acids; unsaturated fatty
acids (UFA)   % unsaturated fatty acids; monounsaturated fatty
acids (MUFA)   % of monoenoic fatty acids; polyunsaturated n-3
fatty acids (PUFAn-3)   % of polyunsaturated fatty acids n-3 series;
polyunsaturated n-6 fatty acids (PUFAn-6)   % of polyunsaturated
fatty acids n-6 series; average chain length [(% Total14 14) . . .
( % totaln  n)]/100 (n  carbon atom number); peroxidizability
index [(mol % monoenoic 0.025) (mol % dienoic 1) (mol
% trienoic  2)  (mol % tetraenoic  4)  (mol % pentaenoic  6) 
( mol % hexaenoic  8)] (11).
Statistical analyses—All statistics were performed using the SPSS
software (SPSS Inc., Chicago, IL). Differences between groups were
analyzed by the Student’s t tests. Correlations between variables were
evaluated by the Pearson’s statistic. The 0.05 level was selected as the
point of minimal statistical significance in every comparison.
RESULTS
Western Blot Analyses of Brain Proteins Show Differences
in DNP-reactive Carbonyls Depending on Sample
Preparation and in RAGE Both Expression and
Electrophoretical Mobility
The Western blot analyses of total homogenates did not show
major differences in the distribution of oxidative damage (Fig.
1A). However, and stressing the importance of sample prepa-
ration for carbonyl analyses, after chloroform treatment sev-
eral bands around 40 to 65 kDa showed increased oxidative
damage in AD samples (Fig. 1A). To know which of these
DNP-reactive carbonyls were related to glycoxidation or re-
lated reactions, we performed Western blots with different
anti-AGE preparations. Staining with a polyclonal anti-AGE
did not reveal any evident difference. Nonetheless, AD samples
exhibited increased glycoxidative (6D12 antibody) damage, and
the targets of these modifications showed diverse molecular
masses, from 30 to 50 kDa (Fig. 1B). In accordance with in-
creased AGE formation, immunoblotting for RAGE demon-
strated three major bands at 30, 50, and 60 kDa in AD cases,
whereas as control specimens only showed one lower molecular
weight band occasionally (Fig. 1C).
TABLE II
Fatty acid composition and derived indexes in brain samples from AD
patients and control individuals
Values shown are mean  S.E. ACL, average chain length; SFA,
saturated fatty acids; UFA, unsaturated fatty acids; PUFA n-6/n-3,
polyunsaturated fatty acids n-6 or n-3 series; DBI, double bond index.
Fatty acid Control AD
14:0 0.59  0.06 0.48  0.02a
16:0 16.60  0.15 19.81  0.66a
16:1n-7 1.76  0.11 1.19  0.01a
18:0 23.67  0.35 21.50  0.39a
18:1n-9 26.78  0.12 23.27  0.77a
18:2 n-6 0.66  0.05 0.85  0.10
18:3 n-3 0.12  0.01 0.07  0.003a
20:0 1.97  0.19 1.64  0.16
20:1 0.13  0.01 0.20  0.009
20:2 n-6 0.26  0.02 0.21  0.01a
20:3 n-6 0.76  0.09 0.58  0.02a
20:4 n-6 6.91  0.46 6.91  0.42
22:4 n-6 5.99  0.29 4.68  0.19a
22:5 n-6 0.52  0.09 0.62  0.02
22:5 n-3 0.10  0.006 0.30  0.03a
24:0 0.20  0.03 0.61  0.07a
24:1n-9 1.45  0.15 2.46  0.27a
ACL 18.63  0.02 18.74  0.02
SFA 43.05  0.11 44.06  0.51
UFA 56.94  0.11 55.93  0.51
MUFA 30.14  0.24 27.12  0.74a
PUFA 26.79  0.33 28.80  0.56
PUFA n-6 15.12  0.45 13.88  0.49
PUFA n-3 11.66  0.46 14.92  0.50a
DBI 158.08  1.78 169.55  2.49a
a Indicates significant differences with control group as assessed by
Student’s t test (p  0,05).
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Proteins from Human Brain Cortex Present Structurally
Characterized Oxidation Products and the Amount of
These Modifications Increases with Alzheimer Disease
To offer a more accurate quantitative measurement of oxi-
dation in brain proteins, we used isotope-dilution GC/MS. Pro-
teins from human brain samples contained oxidation products
resulting from metal-catalyzed oxidation, glycoxidation, and
lipoxidation. An analysis of their distribution reveals than the
more abundant products were those derived from metal-cata-
lyzed oxidation, AASA and GSA (almost 95% of measured
markers) (data not shown). GSA stood as the more frequent
modification, with levels being 40-fold higher than of those of
AASA. The mean concentrations of both GSA and AASA were
significantly higher (p  0,001) in brain samples from AD
patients than in control, age-matched individuals (Fig. 2). The
mean concentrations of CEL and CML were also significantly
higher (p  0.01) in brain proteins from AD patients than in
control individuals (Fig. 2). The concentration of MDAL, a
lipoxidation product, was also significantly increased in sam-
ples from AD patients (p  0.001; Fig. 3).
Changes in Fatty Acid Composition Associated with
Alzheimer Disease Favor Lipoxidative
Modification of Proteins
The analyses of fatty acid revealed significant differences
associated with AD in brain samples, both in individual fatty
acids and in global indexes (Table II). The 24:0 and 22:5,
quantitatively minor fatty acids, exhibited 3-fold increases in
their % content in AD samples. The highly peroxidizable doco-
sahexaenoic acid (DHA) also showed a significant increase in
its content (p  0.001; Fig. 3) in these samples. Interestingly,
DHA levels were inversely correlated with docosatetraenoic
acid levels (r  0.89; p  0.0001; Fig. 3). AD samples showed
almost half of the % contents of 18:3 and 16:1, compared with
the control samples. With reference to the derived indexes, AD
samples showed significant decreases for monounsaturated
fatty acids, with subsequent increases in the content of PUFA
of the n-3 family. This resulted in a significantly increased
double bond (Table I) and peroxidizability indexes (Fig. 3).
Different Kinds of Protein Oxidative
Damage Are Correlated
Association between Changes in Fatty Acid-derived Indexes
and Protein Oxidative Damage—After quantitation of protein
oxidation indexes and fatty acid analyses, several significant
correlations were observed (Fig. 4). GSA levels correlated sig-
nificantly with AASA (r  0.86; p  0.0001), with CML (r 
0.73; p  0.007), and with MDAL (r  0.79; p  0.002). This
suggests that protein carbonyl formation is associated also to
glycoxidative and lipoxidative modifications. Furthermore,
GSA concentrations correlated directly to peroxidizability in-
dexes (r  0.69; p  0.01) (Fig. 4), suggesting an association
between lipid peroxidizability and metal-catalyzed modifica-
tion. Interestingly, levels of CML, a mixed glyco and lipoxida-
tion product, are directly correlated with arachidonic acid lev-
els (r  0.62; p  0.03), suggesting that in these samples, lipid
peroxidation could be a major source of CML.
MDAL Formation Targets Several Structural Proteins and
Enzymes with Key Roles in Cellular Homeostasis—After two-
dimensional electrophoresis and Western blot with an anti-
MDAL antibody, the reactivity of several spots already present
in samples from control individuals was increased in brain
cortex proteins from AD patients (Fig. 5). Nonetheless, some
novel spots also appeared in Western blots of these later. Sev-
eral structural proteins, mitochondrial and cytosolic enzymes,
as well as other proteins, were identified after peptide finger-
printing by MALDI (Table III). Among those, several showed
significant increases in MDAL immunostaining in AD samples
such as neurofilament protein L (3-fold), -tubulin (9-fold),
glial fibrillary acidic protein (8-fold), -enolase (2-fold), ubiqui-
nol-cytochrome c reductase complex core protein I (4-fold), and
 chain of ATP synthase (4-fold).
DISCUSSION
Our data support the presence of protein oxidation-derived
markers in brain samples from aged individuals and AD pa-
tients by mass spectrometric evidence. In the present work,
brain proteins have been analyzed, and we found that the
contents of specific carbonyl AASA and GSA in AD samples
were significantly increased. This fact could be related to a
mitochondrial dysfunction that would promote the leakage of
reactive oxygen species, subsequently increasing protein oxida-
tive damage (27). Furthermore, the results agree with those
previously suggesting that increased oxidative damage occurs
in AD (2, 28), although in these reports it affects specifically
some other brain regions such as temporal inferior cortex (29)
or parietal lobe cortex (28). The increase in carbonyl concen-
trations in these reports is lower than that found here for
AASA, but not for GSA. Our mass spectrometric data also
demonstrate an increase in glycoxidative damage in AD. As
glycolytic intermediates generate CML and CEL (7), these find-
ings agree with the key role of glycolysis in brain. Vulnerable
neurons may have increased dicarbonyl products and/or de-
creased turnover of modified proteins (30). These data fit with
increased carbonyl reductase, alcohol dehydrogenase (31), and
pentose-phosphate pathway activities (32) in brains from AD
patients. In addition, recent data stress the potential impor-
tance of glyoxalase I, an enzyme against reactive dicarbonyls,
as a risk factor in AD pathogenesis (33). Coexistence of the
RAGE overexpression with AGE may be a more pathogenically
relevant finding than AGE alone. Increased RAGE expression
in AD samples suggests a pathogenic role for this multiligand
receptor. In some control individuals, anti-RAGE immunoreac-
tivity was not evident or it was limited to a very low molecular
weight that may be related to the 	8-RAGE, a novel secreted
splice variant of RAGE, recently identified in brain astrocytes
and peripheral blood mononuclear cells (34). In clear contrast,
AD samples exhibited a marked increase in immunoreactivity
as well as in the molecular heterogeneity of the immunoreac-
tive forms. These may belong to full-length RAGE (55 kDa) and
to N-terminal RAGE (35 kDa), already identified in human
brain tissue (35). The pathophysiological relevance of these
findings is unknown but it is proposed that RAGE overexpres-
sion may reflect different responses to increased AGE or A
concentrations. Thus, as C-truncated RAGE forms are cytopro-
tective for endothelial cells (36) its overexpression in AD would
constitute a defensive response. In contrast, expression of full-
length RAGE could contribute to the acceleration of neuronal
damage throughout activation of inflammatory responses
and/or the accumulation of A in brain parenchyma (37).
Lipid peroxidation-derived protein damage was also evi-
denced by GC/MS. MDAL appears to be the more sensible
marker, as it increases almost 2-fold in samples from AD pa-
tients. This agrees with previous reports, stating immunohis-
tochemical evidence for pronounced protein modification by
4-hydroxynonenal (38) in correlation with the severity of the
disease (39). In a close relationship, we found that AD samples
exhibit differences in fatty acid content. Thus, increased lipid
peroxidizability index and DHA content sustain increased lipid
peroxidation. It is known that A induces hippocampal neuro-
nal death by a mechanism that requires lipid peroxidation (39).
Disturbances in the metabolism and transport of essential fatty
acids may explain the observed changes (40), but they could
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also originate from a defensive response, because of the neuro-
protective role of DHA in several experimental models (41).
However, this may be a double-edged sword, as DHA is a highly
peroxidizable fatty acid.
We also identified major targets of lipoxidative modification
by using an anti-MDAL antibody in combination with two-
dimensional electrophoresis and MALDI peptide fingerprint-
ing. The results demonstrated the modification of several pro-
teins, some already known to be modified by anti-DNP
immunoreactive compounds (2, 42) and some other novel. As
discussed above, DNP reactivity alone does not discriminate
between sources of oxidative damage. Therefore, it could be
proposed that lipoxidation chemistry contributes significantly
to carbonyl formation measurable by DNP reactivity. It could
be also hypothesized that several types of oxidative damage
simultaneously modify these proteins. A number of cytoskel-
etal proteins were identified as targets of MDAL formation,
including NF-L, whose changes are involved in a murine model
of age-dependent learning and memory deficits (43), -tubulin
and, in a lower extent -tubulin. Prior studies demonstrated
aberrant modifications of -tubulin in AD samples (44). The
electrophoretic motility pattern of glial fibrillary acidic protein
in AD samples, another target of MDAL formation, is complex
because of the presence of different modification and degrada-
tion forms (45). MDAL also modified several enzymes, some
already known to be carbonylated in AD patients, such as
creatine kinase BB, glutamine synthase, ubiquitin C-terminal
hydrolase L-1, and -enolase (42). We also identified neuronal
specific -enolase, which interconverts 2-phosphoglycerate to
phosphoenolpyruvate in glycolysis. Previous works identified
-enolase and -enolase as specifically oxidized/nitrated in AD
brain (42). Abnormalities in tissue bioenergetics have been
FIG. 4. Protein oxidation indexes are strongly correlated. Indexes of protein carbonyl GSA and AASA are strongly correlated (upper panel,
left; r  0.86; p  0.0001). Protein oxidative damage is correlated with protein glycoxidative damage (upper panel, right; r  0.73; p  0.007) and
protein lipoxidative damage (middle panel, left; r  0.79; p  0,002). Lipid composition also influences protein oxidative damage (middle panel,
right; r  0.69; p  0.01) and protein glycoxidative modification (lower panel; r  0.62; p  0.04). AA: arachidonic acid; triangles (Œ) represent
values from samples of AD patients and circles (●) represent values from control samples.
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previously linked to AD (46). In this line, a number of mito-
chondrial respiratory enzymes, with key roles in energy home-
ostasis were also targets of MDAL formation. Among these,
ubiquinol-cytochrome c reductase complex core protein I is a
major component of the mitochondrial oxidative phosphoryla-
tion complex III. ATP synthase ( chain) showed increased
MDAL formation. Recent data point out that some ATP syn-
thase chains accumulate in cytosol of degenerating neurons, in
some cases in a tight association with  aggregates (47). Crea-
tine kinase is also modified in brain from AD patients and
experimental models (2, 42). The fact that vitamin E inhibits
the AD-associated loss of activity of creatine kinase, strongly
suggests a role for lipid peroxidation in this failure, further
implicating the protein lipoxidative modification (13, 48). Glu-
tamate synthase activity, with a key role in elimination of free
ammonia in brain, is also decreased by AD, especially in glia
FIG. 5. Brain cortex protein lipoxidative modifications in AD patients and a control population. Identification of major targets. Brain
cortex proteins were separated by two-dimensional electrophoresis and anti-MDAL Western blot was performed. Silver stain of membranes is also
shown. Major damaged proteins from control and AD samples were identified by mass spectrometry (Table III).
TABLE III
Identification of major targets of lipoxidative damage in brain cortex
Spota Protein Mr/PI
Peptides
identified Specific lipoxidation
b Accession
number
% control
Cytoskeletal proteins
a Neurofilament triplet L 61777/4.7 21 350  60 P07196
b Vimentin 53686/5.1 36 NS P08670
c Tubulin 2 49831/5.8 19 187  30 P05217
d -Tubulin 1 50151/5.0 15 958  123 P05209
-Tubulin 4 49924/5.0 P05215
-Tubulin 6 49898/5.0 Q9BQE3
e -Actin 41738/5.3 13 NS P02570
-Actin 41793/5.3 P02571
f Glial fibrillary acidic protein 49881/5.4 18 817  42 P14136
Metabolism/Energy
production
g -Enolase 47269/4.9 8 257  37 P09104
h -Enolase 47169/7.0 15 NS P06733
i Ubiquinol-cytochrome c
reductase complex core
protein I
52619/6.0 15 429  55 P31930
j ATP synthase ( chain) 56560/5.3 19 412  38 P06576
k Creatine kinase, B chain (B-CK) 42645/5.3 15 153  34 P12277
l Glutamine synthetase 42065/6.4 14 144  22 P15104
m Glutamate dehydrogenase 1 61398/7.7 16 NS P00367
Other
n Guanine nucleotide-binding
protein G(I)/G(S)/G(T) 
37377/5.6 7 NS P04901
Subunit1 or 2 37331/5.6 P11016
o 60-kDa heat shock protein 61055/5.7 14 134  56 P10809
p Dihydropyrimidinase-related
protein-2 (DRP-2)
62294/6.0 18 NS Q16555
a Spot letter refers to two-dimensional gels obtained from brain cortex samples (Fig. 1).
b For each protein, individual anti-MDAL immunostain/protein values (obtained from each of four AD and four control samples) were averaged
and expressed as percentage of control  S.E. (p  0,05 between control and AD samples by Student’s t test).
c NS, nonsignificant differences.
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close to the affected areas (49). Glutamate synthase interacts
with A, enhancing its prooxidant properties and leading to
lipid peroxidation (50), potentially explaining MDAL formation
in this protein. In accordance with disturbances in glutamate
metabolism as mediators in AD pathogenesis, another enzyme
related to this neurotransmitter, glutamate dehydrogenase,
was also modified with MDAL in AD samples. Other proteins,
such as HSP60 and DRP2, were also identified as targets of
MDAL formation. Our results, as well as others (42), suggest a
pathogenic role for lipoxidative damage, affecting mitochon-
drial homeostasis and axon and neurite wiring.
Collectively, the results presented here support a role for
both protein oxidative damage and changes in fatty acid com-
position in AD pathogenesis, with possible implications of
RAGE. This would lead to disturbances in cytoskeleton and
energy production, which ultimate would contribute to the
generation of neurofibrillary tangles with the participation of
lipid peroxidation.
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